We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Aqueous Humor Is Superior to Blood to Diagnose Retinoblastoma

By LabMedica International staff writers
Posted on 25 Nov 2019
Retinoblastoma is a cancer that forms in the light-detecting cells in the back of the eye. More...
It often appears in children under two years of age and can lead to blindness or eye removal. Most cancers are biopsied and studied so that medical scientists can design targeted treatments.

When there is a family history of retinoblastoma, a child is most likely to develop the disease within 28 months of birth. When there is no family history, it is frequently the parents who notice the main symptoms of retinoblastoma: a white pupil reflex instead of a normal black pupil or red reflex, or a crossed eye.

Ophthalmologists at the Children's Hospital Los Angeles (Los Angeles, CA, USA) and their associates performed whole genome sequencing on 20 matched blood and aqueous samples. Tumor-associated chromosomal changes were found in 0/20 blood versus 11/20 aqueous samples along with shorter DNA fragments. The scientists concluded that aqueous humor is superior to blood as a liquid biopsy for retinoblastoma.

Jesse L. Berry, MD, Associate Director of Ocular Oncology at Children's Hospital Los Angeles, and senior author of the study, said, “You can't directly biopsy retinoblastoma. The tumor is like liquid and has cells all over the eye. Plus retinoblastoma cells can spread easily. Direct biopsy can cause relapse or spread of the disease outside of the eye. This makes diagnosis tricky. In the absence of molecular tests, trained ophthalmologists must look for anomalies in the eye and use ultrasound imaging to diagnose the disease.”

Dr. Berry noted that “Many children actually have retinoblastoma tumors in both eyes. If we were to test the blood and find a positive result, we would not actually know which eye it was from. Instead, aqueous humor biopsies give us specific information for tumors in each eye. Not only can tumor DNA be detected, but the study also showed that genetic factors can predict treatment success for a given tumor. Taken together, the discoveries are set to drastically improve retinoblastoma research and clinical practice.”

"Aqueous humor biopsy has potential to becoming the new standard of care for retinoblastoma," said Dr. Berry. "It is our best chance to diagnose and treat these patients on a molecular level.” The study was published on October 30, 2019 in the journal Ophthalmology.

Related Links:
Children's Hospital Los Angeles


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Aspiration System
VACUSAFE
New
Automated Immunoassay Analyzer
SuperFlex™
Electrolyte Analyzer
BKE-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: LVOne uses blood-based biomarkers to detect stroke and identify large vessel occlusion before hospital arrival, providing objective results earlier than traditional assessments. (Photo courtesy of UpFront Diagnostics)

First-of-Its-Kind Rapid Blood Test Gains CE Mark to Support Prehospital Stroke Triage

Rapid stroke identification before hospital arrival is critical because treatment efficacy declines with every minute of delay. However, definitive assessment typically requires hospital-based imaging,... Read more

Molecular Diagnostics

view channel
Image Credit: iStock

Mpox Analysis Reveals Substantial Suspected False Positives Associated with Contamination

Reliable confirmation of mpox can be difficult where multiple rash-causing illnesses co-circulate and laboratory capacity is limited. Although PCR is central to case detection, contamination during specimen... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: Ebola remains a rapidly evolving public health threat with high mortality, underscoring the need for timely diagnosis and decentralized testing closer to patients (Image Credit: Adobe Stock)

Collaboration Targets Blood-Based Ebola Detection Outside Central Laboratories

Co-Diagnostics, Inc. (Salt Lake City, UT, USA) and ReadyGo Diagnostics Ltd. (Bath, UK) have initiated a collaboration to evaluate ReadyGo’s GoCollect with the Co-Dx PCR platform for blood-based molecular... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Central to the collaboration is the Enhanced Liver Fibrosis (ELF) test, a noninvasive blood test authorized in the U.S. to assess disease progression risk in patients with advanced fibrosis due to MASH and support patient management decisions. (Photo courtesy of Siemens Healthineers)

Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing

Metabolic dysfunction‑associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‑associated steatohepatitis (MASH), affect millions and are linked to obesity, type 2 diabetes,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.